EQUIRAB 1000 I.U

Indications

• Post-exposure prophylaxis following animal bites or exposure to rabies suspected animals
• Pre-exposure prophylaxis for individuals at high risk of rabies exposure, such as veterinarians and animal handlers

Dosage

Children: Refer to specific guidelines for pediatric dosing based on age and weight, as well as the nature of exposure.

Adults: Refer to specific guidelines for post-exposure prophylaxis and pre-exposure prophylaxis, as doses can vary based on the individual's exposure risk and vaccination status.

Mechanism of action

Antirabies vaccines contain inactivated or attenuated strains of the rabies virus, which provoke an immune response. The vaccine triggers the body to produce specific antibodies against the rabies virus glycoprotein, leading to the development of immunological memory. Upon exposure to the virus, the immune system can respond more quickly and effectively.

Pharmacodynamics

The pharmacodynamic action of antirabies vaccines is primarily the induction of an immune response, characterized by the production of neutralizing antibodies. The immune response typically peaks within 2 to 4 weeks after vaccination. The duration of immunity may vary, but it can last for several years in individuals who have received the complete vaccination series.

Pharmacokinetics

The pharmacokinetics of antirabies vaccines involve the intramuscular administration of the vaccine, leading to systemic absorption. The vaccine components are processed by antigen-presenting cells, which subsequently activate T cells and stimulate B cells to produce antibodies. The half-life of the antibodies produced can vary, but they generally remain detectable for an extended period following immunization.

Adverse effects

• Injection site reactions
• Fever
• Headache
• Nausea
• Malaise

Precautions

• Use with caution in individuals with a history of allergic reactions to vaccines
• Monitor for allergic reactions post-administration

Pregnancy

Safety in pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Limited data available, consult healthcare provider before use.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Intradermal vaccine
• Intramuscular vaccine

Indications

• Autism Spectrum Disorders
• Attention Deficit Hyperactivity Disorder (ADHD)
• Post-Traumatic Stress Disorder (PTSD)
• Anxiety Disorders
• Depression
• Cerebral Palsy
• Physical Rehabilitation

Dosage

Children: Refer to the specific therapeutic regimen determined by a healthcare professional, as equine therapy is individualized based on patient needs.

Adults: Refer to the specific therapeutic regimen determined by a healthcare professional, as equine therapy is individualized based on patient needs.

Mechanism of action

Equine therapy operates on several levels. The physical interaction with horses can enhance gross motor skills and encourage physical fitness. Psychologically, the bond formed between horse and human can foster emotional healing, reduce anxiety, and build confidence. The rhythmic motion of riding has been shown to have a calming effect on individuals, mimicking similar movements to those experienced in a therapeutic setting. Moreover, the social interaction involved in caring for and riding horses may improve communication skills and socialization.

Pharmacodynamics

Equine therapy itself does not involve pharmacological agents; however, it may influence the psychobiological pathways in the body. The interactions evoke hormonal responses that can alter levels of cortisol and adrenaline, enhancing relaxation and reducing stress. The therapeutic environment can also promote the release of endorphins, contributing to a sense of well-being and happiness.

Pharmacokinetics

As equine therapy does not involve drugs, pharmacokinetics is not applicable. However, the effects on the body can vary based on individual patient characteristics, the specific condition treated, and the duration and frequency of the therapy sessions. Factors such as age, physical condition, and psychological state can influence therapeutic outcomes.

Pregnancy

Equine products should be used with caution during pregnancy, as there is limited data on their safety. Consultation with a healthcare professional is recommended.

Breast-feeding

Safety during breastfeeding is not well established; therefore, caution is advised when using equine products in nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Cancer therapy
• Immunotherapy
• Wound healing
• Hormonal therapies
• Metabolic disorders

Dosage

Children: Dosing for paediatric patients is dependent on the specific fragment and indication; consult pediatric dosing references or clinical guidelines for appropriate dosing.

Adults: Dosing for fragments varies widely based on the specific type and use case; refer to specific product information or clinical guidelines for accurate dosing.

Mechanism of action

The mechanism of action of fragments varies widely depending on the specific fragment in question. Generally, peptide fragments can interact with specific receptors on cell surfaces, modulating signaling pathways and biological responses. For example, some fragments may act as agonists or antagonists at hormone receptors, influencing processes such as metabolism, growth, and immune responses. Additionally, fragments can enhance or inhibit protein-protein interactions, affecting cellular activities.

Pharmacodynamics

Pharmacodynamics of fragments is largely dependent on their structure and the biological targets they engage. Fragments may exhibit dose-dependent effects, and their potency can be influenced by factors such as their affinity for receptors, their ability to penetrate cellular membranes, and their stability in biological systems. The biological activity can range from promoting cellular proliferation and differentiation to inducing apoptosis in cancer cells.

Pharmacokinetics

The pharmacokinetics of fragments can vary considerably. Generally, they may have a shorter half-life compared to full-length proteins due to their smaller size and potential for faster metabolism. Absorption can occur via various routes, including oral, subcutaneous, or intravenous administration, depending on the formulation. Distribution is influenced by their hydrophilicity or lipophilicity, while elimination typically involves renal clearance or degradation by proteolytic enzymes.

Pregnancy

Safety in pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Caution is advised. It is recommended to consult with a healthcare professional before use.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Primary immunodeficiency disorders
• Secondary immunodeficiency (e.g. due to HIV infection)
• Chronic inflammatory demyelinating polyneuropathy (CIDP)
• Immune thrombocytopenic purpura (ITP)
• Kawasaki disease
• Prevention of infections in at-risk populations (e.g. following bone marrow transplant)

Dosage

Children: Refer to the BNF for Children for age-appropriate dosing guidelines; specific doses depend on the clinical condition and patient age.

Adults: Refer to specific guidelines for dosing based on indication; typically varies based on clinical scenario and patient condition.

Mechanism of action

Immunoglobulin exerts its effects primarily through the neutralization of pathogens and toxins, opsonization, and the activation of the complement system. It modulates immune responses by influencing the activity of various immune cells, including B cells, T cells, and macrophages, thereby enhancing antibody production and regulating inflammation.

Pharmacodynamics

The pharmacodynamics of immunoglobulin involve its ability to bind to specific antigens, effectively neutralizing them and facilitating their clearance. It also plays a crucial role in modulating the immune response, providing immediate passive immunity and promoting the establishment of active immunity over time. The diverse mechanisms through which immunoglobulin operates include antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of pro-inflammatory cytokines.

Pharmacokinetics

Immunoglobulin is typically administered intravenously or subcutaneously. After administration, it is distributed throughout the extracellular space. The half-life of immunoglobulin varies but is generally in the range of 21 to 30 days, depending on the specific formulation and the patient's individual characteristics. It is primarily eliminated through the reticuloendothelial system, with catabolism occurring in various tissues.

Contra-indications

• Hypersensitivity to immunoglobulin preparations
• Selective IgA deficiency with a history of hypersensitivity
• Severe hyperprolinemia

Adverse effects

• Headache
• Nausea
• Fever
• Chills
• Fatigue
• Rash
• Anaphylactic reactions
• Thromboembolic events

Interactions

• Live attenuated vaccines may be less effective if administered concurrently with immunoglobulin therapy
• Caution is advised when administering with other blood products

Precautions

• Monitor for signs of anaphylaxis during and after administration
• Use with caution in patients with renal impairment
• Hydrate adequately to prevent renal dysfunction
• Consider the risk of thrombosis in patients with a history of thromboembolic events

Pregnancy

Immunoglobulin can be used during pregnancy if indicated, as it is considered safe based on available data.

Breast-feeding

Immunoglobulin is excreted in breast milk, but is generally considered safe during breastfeeding.

Storage

Store at 2-8 degrees Celsius. Do not freeze. Protect from light. Use before expiry date.

Formulations

• Intravenous immunoglobulin (IVIG)
• Subcutaneous immunoglobulin (SCIG)
• Intramuscular immunoglobulin (IMIG)